The OncotypeDx assay guides chemotherapy decisions for ER+/HER2− breast cancer patients, but uptake is low, which may contribute to treatment inequities. Van Alsten and colleagues found that Black women, women with low incomes, and women living in high neighborhood deprivation areas were less likely to receive OncotypeDx. Untested women received chemotherapy more frequently, despite similar tumor characteristics. Among untested women, racial disparities were evident in chemotherapy use. Disparities were not observed among those who received testing. These results suggest that unequal access to genomic testing negatively impacts care quality, exacerbating disparities by race and socioeconomic status.
Digital mammography has replaced film mammography in breast-screening programs globally, including Australia. Farber and colleagues aimed to compare tumor characteristics for screen-detected and interval cancers diagnosed under digital mammography compared to film mammography accounting for temporal trends. Rates of early-stage and intermediate-sized interval cancers increased, and late-stage and large interval cancers...